Cartesian Therapeutics (RNAC) Stock Overview
A clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
RNAC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cartesian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.53 |
| 52 Week High | US$15.57 |
| 52 Week Low | US$5.60 |
| Beta | 0.56 |
| 1 Month Change | 42.64% |
| 3 Month Change | 31.84% |
| 1 Year Change | -18.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.43% |
Recent News & Updates
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet
Summary Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for autoimmune diseases and strong insider/institutional support. RNAC’s lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b, surpassing current biologics in durability and efficacy. The ongoing Phase 3 AURORA trial, with FDA SPA agreement and 100 patients, is a pivotal binary catalyst; $126.9M cash runway extends into mid-2027. RNAC’s valuation reflects deep discount to potential, but risks include Phase 3 failure, dilution, and competitive threats from both established and emerging CAR-T players. Read the full article on Seeking AlphaWill Cartesian Therapeutics (NASDAQ:RNAC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Recent updates
Shareholder Returns
| RNAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 23.1% | 0.1% | 2.6% |
| 1Y | -18.3% | 35.5% | 26.2% |
Return vs Industry: RNAC underperformed the US Biotechs industry which returned 42% over the past year.
Return vs Market: RNAC underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| RNAC volatility | |
|---|---|
| RNAC Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RNAC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RNAC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 75 | Carsten Brunn | www.cartesiantherapeutics.com |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma.
Cartesian Therapeutics, Inc. Fundamentals Summary
| RNAC fundamental statistics | |
|---|---|
| Market cap | US$254.15m |
| Earnings (TTM) | -US$151.77m |
| Revenue (TTM) | US$1.78m |
Is RNAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNAC income statement (TTM) | |
|---|---|
| Revenue | US$1.78m |
| Cost of Revenue | US$62.82m |
| Gross Profit | -US$61.05m |
| Other Expenses | US$90.73m |
| Earnings | -US$151.77m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.17 |
| Gross Margin | -3,439.32% |
| Net Profit Margin | -8,550.65% |
| Debt/Equity Ratio | 0% |
How did RNAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 09:11 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cartesian Therapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| John Newman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |